Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: Report of two cases and review of the literature

Kalyani Narra; Hossein Borghaei; Tahseen Al-Saleem; Martin Höglund; Mitchell R. Smith

doi:10.1016/j.leukres.2005.05.017

Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: Report of two cases and review of the literature

Kalyani Narra, Hossein Borghaei, Tahseen Al-Saleem, Martin Höglund, Mitchell R. Smith

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Pure red cell aplasia (PRCA) is an unusual cause of anemia in patients with chronic lymphoproliferative disorders. Here, we present two cases of PRCA, one associated with chronic lymphocytic leukemia (CLL) and the other with splenic marginal zone lymphoma, in which the PRCA responded dramatically to treatment with rituximab. We then review the literature on PRCA in lymphoma and response to rituximab. PRCA associated with CLL or lymphoma may be another indication for rituximab therapy.

Original language	English
Pages (from-to)	109-114
Number of pages	6
Journal	Leukemia Research
Volume	30
Issue number	1
DOIs	https://doi.org/10.1016/j.leukres.2005.05.017
State	Published - Jan 2006

Keywords

Antibodies, Monoclonal, Murine-Derived
Antibodies, Monoclonal/administration & dosage
Antineoplastic Agents/administration & dosage
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell/complications
Lymphoma/complications
Middle Aged
Red-Cell Aplasia, Pure/complications
Rituximab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2005.05.017

Cite this

@article{43369a387d8f413dbaee980f9a25005c,

title = "Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: Report of two cases and review of the literature",

abstract = "Pure red cell aplasia (PRCA) is an unusual cause of anemia in patients with chronic lymphoproliferative disorders. Here, we present two cases of PRCA, one associated with chronic lymphocytic leukemia (CLL) and the other with splenic marginal zone lymphoma, in which the PRCA responded dramatically to treatment with rituximab. We then review the literature on PRCA in lymphoma and response to rituximab. PRCA associated with CLL or lymphoma may be another indication for rituximab therapy.",

keywords = "Antibodies, Monoclonal, Murine-Derived, Antibodies, Monoclonal/administration & dosage, Antineoplastic Agents/administration & dosage, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell/complications, Lymphoma/complications, Middle Aged, Red-Cell Aplasia, Pure/complications, Rituximab",

author = "Kalyani Narra and Hossein Borghaei and Tahseen Al-Saleem and Martin H{\"o}glund and Smith, {Mitchell R.}",

year = "2006",

month = jan,

doi = "10.1016/j.leukres.2005.05.017",

language = "English",

volume = "30",

pages = "109--114",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "1",

}

TY - JOUR

T1 - Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab

T2 - Report of two cases and review of the literature

AU - Narra, Kalyani

AU - Borghaei, Hossein

AU - Al-Saleem, Tahseen

AU - Höglund, Martin

AU - Smith, Mitchell R.

PY - 2006/1

Y1 - 2006/1

N2 - Pure red cell aplasia (PRCA) is an unusual cause of anemia in patients with chronic lymphoproliferative disorders. Here, we present two cases of PRCA, one associated with chronic lymphocytic leukemia (CLL) and the other with splenic marginal zone lymphoma, in which the PRCA responded dramatically to treatment with rituximab. We then review the literature on PRCA in lymphoma and response to rituximab. PRCA associated with CLL or lymphoma may be another indication for rituximab therapy.

AB - Pure red cell aplasia (PRCA) is an unusual cause of anemia in patients with chronic lymphoproliferative disorders. Here, we present two cases of PRCA, one associated with chronic lymphocytic leukemia (CLL) and the other with splenic marginal zone lymphoma, in which the PRCA responded dramatically to treatment with rituximab. We then review the literature on PRCA in lymphoma and response to rituximab. PRCA associated with CLL or lymphoma may be another indication for rituximab therapy.

KW - Antibodies, Monoclonal, Murine-Derived

KW - Antibodies, Monoclonal/administration & dosage

KW - Antineoplastic Agents/administration & dosage

KW - Female

KW - Humans

KW - Leukemia, Lymphocytic, Chronic, B-Cell/complications

KW - Lymphoma/complications

KW - Middle Aged

KW - Red-Cell Aplasia, Pure/complications

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=27844595867&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2005.05.017

DO - 10.1016/j.leukres.2005.05.017

M3 - Article

C2 - 16043218

AN - SCOPUS:27844595867

SN - 0145-2126

VL - 30

SP - 109

EP - 114

JO - Leukemia Research

JF - Leukemia Research

IS - 1

ER -

Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: Report of two cases and review of the literature

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this